Investors of Nektar Therapeutics Stock May Have Legal Claims – NKTR

Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation

Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics (“Nektar” or “Nektar Therapeutics”) (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.

The investigation concerns whether members of Nektar’s board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.

INVESTORS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR NKTR STOCK SINCE AT LEAST JUNE 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR NKTR SECURITIES.

SHAREHOLDERS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR STOCK SINCE AT LEAST JUNE 2022 ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.